Tenon Medical (NASDAQ:TNON) Posts Quarterly Earnings Results, Misses Expectations By $1.17 EPS

Tenon Medical (NASDAQ:TNON) released its quarterly earnings data on Thursday. The company reported ($5.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.22) by ($1.17), FiscalAI reports. Tenon Medical had a negative return on equity of 907.60% and a negative net margin of 257.85%. The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.55 million.

Here are the key takeaways from Tenon Medical’s conference call:

• Revenue and gross margin grew: Third-quarter revenue increased 22% year over year to $1.4 million, while gross margin rose to 66.3%. The company said operating expenses fell year over year and its operating loss improved to $3.1 million.
• Net loss widened: Third-quarter net loss was $6.6 million, compared with $3.3 million a year earlier, primarily due to non-cash warrant inducement expense and convertible-note interest expense.
• Debt repaid and capital raised: Tenon raised approximately $15.6 million in gross proceeds during the quarter and repaid its convertible notes in full, leaving no debt at quarter-end. It also reported about $7.1 million of availability under its ATM program.
• Commercial and product expansion underway: The company appointed a new chief revenue officer and fully launched its 3D-printed SImmetry+ lateral screw, which generated about $1.2 million during its limited launch. It is targeting a first-quarter 2027 market release for Quickstep and expects to submit an additional SImmetry+ enhancement in early December.

Tenon Medical Price Performance

NASDAQ:TNON traded up $0.04 during trading hours on Thursday, reaching $1.79. The company had a trading volume of 119,521 shares, compared to its average volume of 1,962,461. Tenon Medical has a 1-year low of $1.57 and a 1-year high of $44.80. The business’s 50 day moving average price is $3.10 and its 200-day moving average price is $15.88. The firm has a market cap of $4.81 million, a PE ratio of -0.04 and a beta of 1.43.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tenon Medical in a report on Thursday, October 15th. Wall Street Zen lowered Tenon Medical from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold”.

Insider Activity at Tenon Medical

In other news, major shareholder Financial Lp Hrt sold 65,582 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $5.56, for a total transaction of $364,635.92. Following the sale, the insider owned 15,839 shares of the company’s stock, valued at $88,064.84. This trade represents a 80.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have purchased 129,945 shares of company stock worth $500,468 and have sold 136,599 shares worth $605,467. 17.71% of the stock is owned by insiders.

About Tenon Medical

Tenon Medical, Inc. (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain. The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.